Correlation Between Non-motor Symptoms and Malnutrition in Patients With Parkinson's Disease

Zhejiang University

Status: Unknown

Conditions: Parkinson Disease

Study type: Observational

Funder types: Other

Identifiers

NCT04934592

2020-376

Details and patient eligibility

About

This study used Mini Nutrition Assessment (MNA) , Nutrition risk screening 2002(NRS-2002) and Non-motor Symptom Quest (NMSquest) to investigate the nutritional status of patients with Parkinson's disease, to analyze the correlation between non-motor symptoms and malnutrition in patients with Parkinson's disease (PD) , and to provide evidence for clinical treatment and early nutritional intervention.

Full description

Data were collected by questionnaire survey.For arkinson patients who were admitted to the facility between June 2020 and July 2021 were targeted. This study used convenience sampling and included criteria: length of stay > 24 hours; Parkinson patients who met Chinese diagnostic criteria for Parkinson's disease (2016 edition) ; willing participants and able to complete the scale. Exclusion criteria: parkinsonism caused by cerebrovascular disease, encephalitis, traumatic brain injury, complete transfusion of blood, plasma, albumin within one month, severe gastrointestinal disease, metabolic disease, and other wasting diseases; Patients with critical illness, severe cognitive impairment, and inability to communicate. The study was approved by the medical ethics committee with the informed consent of all selected individuals and their families

Enrollment: 85 estimated patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Length of stay > 24 hours; Parkinson patients who met Chinese diagnostic criteria for Parkinson's disease (2016 edition) ; willing to participate in the study and able to complete the scale.

Exclusion criteria

• Parkinson's disease caused by cerebrovascular disease, Encephalitis, traumatic brain injury; patients who have received whole blood, plasma, albumin within one month; patients with severe gastrointestinal disease, metabolic disease and other wasting diseases; Patients with critical illness, severe cognitive impairment, and inability to communicate.